Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Published:2014-03 Issue:3 Volume:30 Page:204-221
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Zhang Mei¹,Zhang Lin²,Wu Bin¹,Song Haolan¹,An Zhenmei³,Li Shuangqing⁴

Affiliation:

1. Department of Laboratory Medicine, West China Hospital; Sichuan University; Chengdu 610041 Sichuan Province China

2. The Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine; Chengdu Sichuan Province China

3. Department of Endocrinology and Metabolism, West China Hospital; Sichuan University; Chengdu 610041 Sichuan Province China

4. Golden Card Section, West China Hospital; Sichuan University; Chengdu 610041 Sichuan Province China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/dmrr.2479/fullpdf

Reference15 articles.

1. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials;Musso;Ann Med,2012

2. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers applicability of a novel insulin-independent treatment;Wilding;Diabetes Care,2009

3. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes;List;Diabetes Care,2009

4. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial;Ferrannini;Diabetes Care,2010

5. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial;Bailey;Lancet,2010

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice;Experimental and Therapeutic Medicine;2024-02-28

2. ADMIRE Study: Dapagliflozin and Metformin Fixed-dose Combination as Initial Choice of Therapy in Type 2 Diabetes Mellitus: A Real-world Study;Chronicle of Diabetes Research and Practice;2024-01

3. Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action;Journal of Cardiovascular Development and Disease;2023-06-22

4. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials;European Journal of Clinical Pharmacology;2023-04-25

5. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study;Diabetes, Obesity and Metabolism;2023-04-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3